Cargando…

The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma

Multiple myeloma (MM), accounting for ~1% of all types of human cancer and 13% of all hematological malignancies, is characterized by the malignant proliferation of monoclonal plasma cells (PCs) in the bone marrow. MM leads to end stage organ impairment, including bone lesions, renal dysfunction, hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Bingying, Ju, Shaoqing, Chu, Haidan, Shen, Xianjuan, Zhang, Yan, Luo, Xi, Cong, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920744/ https://www.ncbi.nlm.nih.gov/pubmed/29731841 http://dx.doi.org/10.3892/ol.2018.8157

Ejemplares similares

MicroRNAs in urine are not biomarkers of multiple myeloma
por: Sedlaříková, Lenka, et al.
Publicado: (2015)

Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma
por: Jones, C I, et al.
Publicado: (2012)

Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer
por: Jin, Chunjing, et al.
Publicado: (2016)

PCAT‐1 promotes cell growth by sponging miR‐129 via MAP3K7/NF‐κB pathway in multiple myeloma
por: Shen, Xianjuan, et al.
Publicado: (2020)

MicroRNAs: New Players in Multiple Myeloma
por: Pichiorri, Flavia, et al.
Publicado: (2011)

Circulating microRNAs and Their Role in Multiple Myeloma
por: Federico, Cinzia, et al.
Publicado: (2019)

The Regulation of microRNAs in Alzheimer's Disease
por: Kou, Xianjuan, et al.
Publicado: (2020)

Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma
por: Zhang, Wenjing, et al.
Publicado: (2014)

Regulatory effects of lncRNAs and miRNAs on autophagy in malignant tumorigenesis
por: Yin, Qingqing, et al.
Publicado: (2018)

MicroRNAs in Huntington’s Disease: Diagnostic Biomarkers or Therapeutic Agents?
por: Dong, Xiaoyu, et al.
Publicado: (2021)

Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma
por: Soliman, Amro M., et al.
Publicado: (2020)

Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways
por: Shen, Xianjuan, et al.
Publicado: (2019)

Circulating microRNAs Correlate with Multiple Myeloma and Skeletal Osteolytic Lesions
por: Moura, Sara Reis, et al.
Publicado: (2021)

LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p
por: Pan, Yafang, et al.
Publicado: (2019)

Circulating lncRNA DANCR as a potential auxillary biomarker for the diagnosis and prognostic prediction of colorectal cancer
por: Shen, Xianjuan, et al.
Publicado: (2020)

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis
por: Solly, Emma L., et al.
Publicado: (2019)

The Role of microRNAs in Cancer: Functions, Biomarkers and Therapeutics
por: Tucci, Paola
Publicado: (2022)

MicroRNAs as biomarkers in glaucoma and potential therapeutic targets
por: Martinez, Bridget, et al.
Publicado: (2022)

Exosomal circRNAs: Sorting Mechanisms, Roles and Clinical Applications in Tumors
por: Xu, Yanhua, et al.
Publicado: (2020)

Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background
por: Papanota, Aristea-Maria, et al.
Publicado: (2021)

Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2021)

Circulating microRNAs as Biomarkers, Therapeutic Targets, and Signaling Molecules
por: Ajit, Seena K.
Publicado: (2012)

MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
por: Daoud, Afra Z., et al.
Publicado: (2019)

Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma
por: Sorop, Andrei, et al.
Publicado: (2021)

MicroRNAs as Biomarkers and Therapeutic Targets for Acute Kidney Injury
por: Tsuji, Kenji, et al.
Publicado: (2023)

MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020)

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma
por: Bi, Chonglei, et al.
Publicado: (2015)

Circulating MicroRNAs: Potential Biomarkers for Cancer
por: Yu, De-Cai, et al.
Publicado: (2011)

A Challenge to Aging Society by microRNA in Extracellular Vesicles: microRNA in Extracellular Vesicles as Promising Biomarkers and Novel Therapeutic Targets in Multiple Myeloma
por: Yamamoto, Tomofumi, et al.
Publicado: (2018)

MicroRNAs as clinical biomarkers?
por: Angelini, Timothy G., et al.
Publicado: (2015)

MicroRNAs as Biomarkers in Cancer
por: Sundarbose, Kamini, et al.
Publicado: (2013)

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
por: Regev, Keren, et al.
Publicado: (2016)

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
Publicado: (2016)

Multiple microRNAs as biomarkers for early breast cancer diagnosis
por: Jang, Ji Young, et al.
Publicado: (2021)

MicroRNAs as a possible biomarker in the treatment of multiple sclerosis
por: Pérez, Moisés Manuel Gallardo, et al.
Publicado: (2022)

MicroRNAs Dysregulation and Metabolism in Multiple System Atrophy
por: Xiang, Chunchen, et al.
Publicado: (2019)

MicroRNAs and Multiple Sclerosis
por: Tufekci, Kemal Ugur, et al.
Publicado: (2010)

MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
por: Martinez, Bridget, et al.
Publicado: (2020)

MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?
por: Devaux, Yvan, et al.
Publicado: (2015)

Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy
por: Fan, Baoyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d9q7auik8jpargfia6tf7vhro3